This content is from: Corporate

Derivative poison pills could be invalid

Despite recent reports, US companies will not be rushing to change their shareholder rights plans in the wake of the CSX case. The poison pills would punish the wrong parties and could be invalid

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial